Cypress Asset Management Inc. TX Takes $5.33 Million Position in Johnson & Johnson (NYSE:JNJ)

Cypress Asset Management Inc. TX acquired a new position in Johnson & Johnson (NYSE:JNJ - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 36,126 shares of the company's stock, valued at approximately $5,330,000. Johnson & Johnson accounts for 1.3% of Cypress Asset Management Inc. TX's holdings, making the stock its 22nd biggest position.

Several other large investors have also added to or reduced their stakes in the stock. Ameriflex Group Inc. bought a new stake in shares of Johnson & Johnson in the fourth quarter worth approximately $550,000. United Advisor Group LLC boosted its position in shares of Johnson & Johnson by 17.7% during the fourth quarter. United Advisor Group LLC now owns 6,547 shares of the company's stock worth $947,000 after acquiring an additional 984 shares during the last quarter. American Trust increased its holdings in shares of Johnson & Johnson by 5.7% in the fourth quarter. American Trust now owns 32,514 shares of the company's stock worth $4,702,000 after purchasing an additional 1,764 shares during the last quarter. Putney Financial Group LLC bought a new position in shares of Johnson & Johnson during the 4th quarter valued at approximately $61,000. Finally, Aurdan Capital Management LLC purchased a new stake in shares of Johnson & Johnson during the 4th quarter valued at about $5,296,000. Institutional investors own 69.55% of the company's stock.

Johnson & Johnson Trading Up 0.4%

JNJ traded up $0.53 during trading hours on Thursday, reaching $152.96. The company's stock had a trading volume of 2,353,932 shares, compared to its average volume of 7,931,169. The stock has a market cap of $368.04 billion, a PE ratio of 23.00, a P/E/G ratio of 2.56 and a beta of 0.42. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $169.99. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. The business's 50-day moving average is $154.63 and its 200-day moving average is $153.64.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.59 by $0.18. The firm had revenue of $21.89 billion during the quarter, compared to the consensus estimate of $21.65 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. As a group, equities research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th will be paid a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 3.40%. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date of this dividend is Tuesday, May 27th. Johnson & Johnson's dividend payout ratio is 57.84%.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on JNJ. Barclays reduced their price objective on shares of Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating on the stock in a research report on Thursday, April 17th. Leerink Partners lowered Johnson & Johnson from an "outperform" rating to a "market perform" rating and reduced their price target for the stock from $169.00 to $153.00 in a research report on Tuesday, May 13th. The Goldman Sachs Group upgraded Johnson & Johnson from a "neutral" rating to a "buy" rating and increased their price target for the company from $157.00 to $172.00 in a research note on Wednesday, April 9th. Morgan Stanley raised their price target on shares of Johnson & Johnson from $164.00 to $169.00 and gave the stock an "equal weight" rating in a research report on Wednesday, April 16th. Finally, Guggenheim restated a "neutral" rating on shares of Johnson & Johnson in a research note on Wednesday, April 2nd. Eleven analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $170.88.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.